Hidefumi Wada

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 621 citations · Full text

Cutaneous T-cell Lymphoma, Lymphoid Neoplasia, Medicine +6

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

Naoya Yamazaki, Tatsuya Takenouchi, Manabu Fujimoto et al. · Cancer Chemotherapy and Pharmacology · 2017 · 86 citations · Full text

Phase 1B, Anti-pd-1 Monoclonal Antibody, Medicine +7

Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein

Toru Ogawa, Yoji Nagashima, Hidefumi Wada et al. · Human Pathology · 2005 · 60 citations

Autoimmune Disease, Human Growth, Medicine +7

Radiation therapy for extramammary Paget's disease: treatment outcomes and prognostic factors

Masaharu Hata, Izumi Koike, Hidefumi Wada et al. · Annals of Oncology · 2013 · 54 citations · Full text

Adaptive Radiotherapy, Prognostic Factors, Radiation Medicine +9

Role of Radiotherapy as Curative Treatment of Extramammary Paget’s Disease

Masaharu Hata, Motoko Omura, Izumi Koike et al. · International Journal of Radiation Oncology*Biology*Physics · 2010 · 47 citations

Radiation Medicine, Radiation Therapy, Medicine +7